Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients: A Narrative Review
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of paclitaxel- and taxanes-based chemotherapy, which is generally given to breast cancer and can lead to low quality of life along with neuropathy symptoms even after completion of the chemotherapy treatment.
Methods: In this paper, we present a narrative overview of CIPN, chemotherapy medication that causes neuropathy in breast cancer patients, treatment challenges for CIPN and pathological complications, current trends, and future research challenges, based on expert discussion and a current literature search.
Results: At present, there are no gold-standard treatment protocols available, which has made it more devastating for the patients suffering from breast cancer. The incidence rate of CIPN is 19% to 85% or above, and it can only decrease if treatment is available. Moreover, treatments are available, but only based on the symptoms.
Conclusion: Worldwide, cancer is the primary cause of millions of deaths annually. We still lack an appropriate treatment plan for the adverse effects that follow chemotherapy treatment, despite the fact that cancer treatment has advanced over the last decade. CIPN is one of the most frequent side effects, and the patients will experience symptoms of neuropathy after one or two chemotherapy cycles. Oncology nurses play a very critical role in managing CIPN symptoms but are sometimes overlooked during the assessment period. Managing neuropathic pain, maintaining safety protocol, improving physical function, and proper standardized nursing CIPN treatment protocol should be the primary goals for managing the CIPN.
Full text article
References
Upadhyay A. Cancer: An unknown territory; rethinking before going ahead. Genes Dis.
;8(5):655-661. doi: 10.1016/j.gendis.2020.09.002.
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast
Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current
Treatment Strategies-An Updated Review. Cancers (Basel). 2021;13(17):4287. doi: 10.3390/cancers13174287.
What Is Cancer? [Internet]. Cancer.gov. 2021. Available from: https://www.cancer.gov/about- cancer/understanding/what-is-cancer. [Last accessed on 2024 12 Sep].
Davis CP. Cancer: Symptoms, Causes, Treatment, Stages, Prevention [Internet]. MedicineNet. 2023. Available from: https://www.medicinenet.com/cancer/article.htm. [Last accessed on 2024 12 Sep].
Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022;156(4&5):598-607. doi: 10.4103/ijmr.ijmr_1821_22
Sandler S, Alfino L, Saleem M. The importance of preventative medicine in conjunction with modern day genetic studies. Genes Dis. 2018;5(2):107-111. doi: 10.1016/j.gendis.2018.04.002
Professional CCM. Breast Cancer [Internet]. Cleveland Clinic. Available
from: https://my.clevelandclinic.org/health/diseases/3986-breast-cancer. [Last accessed on
12 Sep].
Ankar RS, Singh S. Chemotherapy Induced Peripheral Neuropathy-A Review. Journal of
Evolution of Medical and Dental Sciences [Internet]. 2020 Oct 19;9(42):3147–3151. doi 10.14260/jemds/2020/689
Velasco R, Santos C, Soler G, et al. Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst. 2016;21(3):134-141. doi: 10.1111/jns.12177
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019;20(6):1451. doi: 10.3390/ijms20061451
Mizrahi D, Park SB, Li T, et al. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Netw Open. 2021;4(2):e2036695. doi: 10.1001/jamanetworkopen.2020.36695
Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest. 2003;21(3):439-451. doi: 10.1081/cnv-120018236
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019;20(6):1451. doi: 10.3390/ijms20061451
Kannan S. Peripheral Neuropathy - Types | Symptoms | Causes | Risk Factors | Treatment
[Internet]. 2023. Available from: https://www.icliniq.com/articles/neurological- health/peripheral-neuropathy. [Last accessed on 2024 13 Sep].
Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018;7(4):379-403. doi: 10.21037/gs.2017.11.04
Fu MR. Breast cancer-related lymphedema: Symptoms, diagnosis, risk reduction, and management. World J Clin Oncol. 2014;5(3):241-247. doi: 10.5306/wjco.v5.i3.241
Velasco R, Bruna J. Taxane-Induced Peripheral Neurotoxicity. Toxics. 2015;3(2):152-169. doi: 10.3390/toxics3020152
Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Experimental Neurology. 2016;288:153–66. doi: 10.1016/j.expneurol.2016.11.015
Sawant A. 4 Questions About Breast Cancer and Peripheral Neuropathy (CIPN). WinSanTor. 2023. Available from: http://winsantor.com/4-questions-about-breast-cancer-
peripheral-neuropathy-cipn/. [Last accessed on 2024 13 Sep].
Hershman DL, Till C, Wright JD, et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016;34(25):3014-3022. doi: 10.1200/JCO.2015.66.2346
Chemo Induced Peripheral Neuropathy. Johns Hopkins Peripheral Nerve Center. Available from: https://www.hopkinsmedicine.org/neurology-neurosurgery/specialty- areas/peripheral-nerve/chemo-induced-peripheral-neuropathy. [Last accessed on 2024 13 Sep].
Gordon-Williams R, Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Res. 2020;9:F1000 Faculty Rev-177. doi: 10.12688/f1000research.21625.1
Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK, Leung KT, Li YC, Wong KH, Suen L, Chan CW, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A.
Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Support Care Cancer.
;27(12):4753-4762. doi: 10.1007/s00520-019-04771-8.
Lavoie Smith EM, Haupt R, Kelly JP, Lee D, Kanzawa-Lee G, Knoerl R, Bridges C, Alberti P, Prasertsri N, Donohoe C. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure. Oncol Nurs Forum. 2017 Sep 1;44(5):580-588. doi: 10.1188/17.ONF.580-588.
Eldridge S, Guo L, Hamre J. A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models. Toxicologic Pathology [Internet]. 2019;48(1):190–201. doi: 10.1177/0192623319861937
Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol. 2013;4:156. Published 2013 Dec 18. doi:10.3389/fphar.2013.00156.
Cavaletti G. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?. Oncologist. 2011;16(12):1667-1668. doi:10.1634/theoncologist.2011-0343
Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer [Internet]. Mayo Clinic. Available from: https://www.mayo.edu/research/clinical-trials/cls-20453011. [Last accessed on 2024 14 Sep].
Kanzawa-Lee GA. Chemotherapy-Induced Peripheral Neuropathy: Nursing Implications. J Infus Nurs. 2020;43(3):155-166. doi: 10.1097/NAN.0000000000000368.
Wheeler HE, Gamazon ER, Wing C, et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013;19(2):491-499. doi: 10.1158/1078-0432.CCR-12-2618.
Wu CJ, Chan YN, Yen LY, et al. Extremity Exercise Program in Breast Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy: A Feasibility Pilot Study. Healthcare (Basel). 2022;10(4):688. doi: 10.3390/healthcare10040688.
Mackereth P, Stringer J. Living with chemotherapy-induced peripheral neuropathy: a nested qualitative study. British Journal of Nursing. 2023;32(20):978–86. doi: 10.12968/bjon.2023.32.20.978.
Kim Schmidt. Chemotherapy-Induced peripheral neuropathy education and assessment [dissertation] south Dakota state university;2015.
Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2010;14(3):E22-E28. doi: 10.1188/10.CJON.E22-E28.
Msn ML RN. How to Perform PQRST Pain Assessments. Simple Nursing. 2024. Available from:https://simplenursing.com/pqrstpain/#:~:text=PQRST%20stands%20for%20Provocation%2C%20Quality,or%20Scale)%2C%20and%20Timing. [Last accessed on 2024 14 Sep].
Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004
Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin J Oncol Nurs. 2013 Apr;17(2):138-44. doi: 10.1188/13.CJON.138-144.
Authors
Copyright (c) 2024 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.